fpr

FPR A14 is an agonist of formyl peptide receptor (FPR) and induces cell differentiation.

FPR Agonist 43 is a dual agonist of formyl peptide receptor 1 and formyl peptide receptor 2 (FPR2)/ALX.

Cefprozil monohydrate (Cefprozil) is a second-generation cephalosporin-type antibiotic.

Cefprozil (Cefzil) is a novel cephalosporin antibiotic with antiviral activity for the study of immune system disorders.

Cofpropamine, a caffeine derivative that inhibits polyadenylation, enhances the suppressive effects of Cyclophosphamide in animal models of rat adjuvant arthritis and mouse collagen-induced arthritis.

FPR1 antagonist 3 (compound 10) is a potent and selective antagonist of FPR1, effectively inhibiting superoxide anion production and elastase release with IC50 values of 0.33 and 0.84 μM, respectively.

FPR2 agonist 2 is a potent FPR2 agonist with blood-brain barrier permeability that acts on h-FPR2 (EC50: 0.13 nM), inhibiting the production of pro-inflammatory cytokines, counteracting changes in mitochondrial function, and inhibiting caspase-3 activity.

Compound 24a, an FPR1 antagonist, demonstrates potent inhibition of the formyl peptide receptor 1 (FPR1) with an IC50 value of 25 nM. It impedes cell proliferation and promotes apoptosis, thereby inhibiting cell growth. This compound also attenuates cell migration and concurrently promotes angiogenesis [1].

Compound 25b, an FPR1 antagonist, exhibits potent inhibition of the formyl peptide receptor 1 with an IC50 of 70 nM. It concurrently hampers cell proliferation and triggers apoptosis, diminishing cell growth and migration, yet paradoxically augments angiogenesis [1].

Compound CMC23, an FPR2 agonist, mitigates lactate dehydrogenase release in LPS-stimulated cultures and reduces pro-inflammatory IL-1β and IL-6 levels. It also attenuates phosphor-STAT3 levels through the STAT3 SOCS3 signaling pathway [1].

Compound 20, also known as FPR2 agonist 4, selectively activates FPR2 with an EC50 of 0.2 nM.

Efprezimod alfa, an active peptide, can be utilized for various biochemical studies.

N-Formyl-Met-Leu-Phe (N-Formyl-MLF) (fMLF) is a synthetic peptide that acts as an agonist at formyl peptide receptors (FPR; Ki = 0.8 pM).

Ac9-25 acetate is an annexin AI peptide and activates the neutrophil reduced nicotinamide adenine dinucleotide phosphate oxidase through FPR but not through FPRL1.

Boc-MLF (TFA) is a specific antagonist of formyl peptide receptor (FPR) and also inhibits signaling through FPRL1 at higher concentrations.

Ebopiprant (OBE022) is an orally available, selective and potent prostaglandin F2α (PGF2α) receptor antagonist that interferes with the binding of PGF0126α to the FPR and can be used in the study of obesity.

L 888607 is an effective and selective CRTH2 agonist (Ki: 0.8 nM).

PD176252 is a potent BB1 and BB2 antagonist with inhibitory effects on BB1 and BB2 receptors.PD176252 acts as a small molecule GRPR inhibitor and FPR1 FPR2 agonist to inhibit the growth and proliferation of a variety of cancer cells.

Tafluprost acid is a selective agonist at the prostaglandin F receptor.

N-Formyl-MMYALF is an effective mitochondrial N-formyl peptide (mtFP) that possesses activity in depleting calcium ions from the endoplasmic reticulum. Additionally, it inhibits the PMN chemotactic response to bacterial peptides mediated by FPR-1.

N-Formyl-MMYALF TFA is a mitochondrial N-formyl peptide known for its ability to deplete calcium ions in the endoplasmic reticulum. Additionally, it inhibits the FPR-1-mediated chemotactic response of PMNs to bacterial peptides.

T0080 is an FPR-1 antagonist. It reduces apoptosis (Apoptosis) and inhibits the production of reactive oxygen species (ROS) and pro-inflammatory cytokines (TNF-α and IL-1β) in plaque macrophages within ApoE−/− mouse models, thereby slowing the progression of atherosclerosis.

Cyclosporin H (CsH), a specific inhibitor of FPR1, inhibited lung inflammation in the ALI models. CsH significantly attenuated MTDs or NFP-induced inflammatory lung injury and activation of MAPK and AKT pathways. Cyclosporin H is a viral transduction enha

{Boc}-Phe-Leu-Phe-Leu-Phe ({Boc}-FLFLF) is a selective antagonist of the formyl peptide receptor (FPR) family, effectively inhibiting receptor activity in response to formyl peptides.